Pulmonary Artery Catheter Use and Risk of In-hospital Death in Heart Failure Cardiogenic Shock.


Journal

Journal of cardiac failure
ISSN: 1532-8414
Titre abrégé: J Card Fail
Pays: United States
ID NLM: 9442138

Informations de publication

Date de publication:
09 2023
Historique:
received: 16 03 2023
revised: 29 04 2023
accepted: 02 05 2023
medline: 18 9 2023
pubmed: 16 5 2023
entrez: 15 5 2023
Statut: ppublish

Résumé

Pulmonary artery catheters (PACs) are increasingly used to guide management decisions in cardiogenic shock (CS). The goal of this study was to determine if PAC use was associated with a lower risk of in-hospital mortality in CS owing to acute heart failure (HF-CS). This multicenter, retrospective, observational study included patients with CS hospitalized between 2019 and 2021 at 15 US hospitals participating in the Cardiogenic Shock Working Group registry. The primary end point was in-hospital mortality. Inverse probability of treatment-weighted logistic regression models were used to estimate odds ratios (ORs) and corresponding 95% confidence intervals (CI), accounting for multiple variables at admission. The association between the timing of PAC placement and in-hospital death was also analyzed. A total of 1055 patients with HF-CS were included, of whom 834 (79%) received a PAC during their hospitalization. In-hospital mortality risk for the cohort was 24.7% (n = 261). PAC use was associated with lower adjusted in-hospital mortality risk (22.2% vs 29.8%, OR 0.68, 95% CI 0.50-0.94). Similar associations were found across SCAI stages of shock, both at admission and at maximum SCAI stage during hospitalization. Early PAC use (≤6 hours of admission) was observed in 220 PAC recipients (26%) and associated with a lower adjusted risk of in-hospital mortality compared with delayed (≥48 hours) or no PAC use (17.3% vs 27.7%, OR 0.54, 95% CI 0.37-0.81). This observational study supports PAC use, because it was associated with decreased in-hospital mortality in HF-CS, especially if performed within 6 hours of hospital admission. An observational study from the Cardiogenic Shock Working Group registry of 1055 patients with HF-CS showed that pulmonary artery catheter (PAC) use was associated with a lower adjusted in-hospital mortality risk (22.2% vs 29.8%, odds ratio 0.68, 95% confidence interval 0.50-0.94) compared with outcomes in patients managed without PAC. Early PAC use (≤6 hours of admission) was associated with a lower adjusted risk of in-hospital mortality compared with delayed (≥48 hours) or no PAC use (17.3% vs 27.7%, odds ratio 0.54, 95% confidence interval 0.37-0.81).

Sections du résumé

BACKGROUND
Pulmonary artery catheters (PACs) are increasingly used to guide management decisions in cardiogenic shock (CS). The goal of this study was to determine if PAC use was associated with a lower risk of in-hospital mortality in CS owing to acute heart failure (HF-CS).
METHODS AND RESULTS
This multicenter, retrospective, observational study included patients with CS hospitalized between 2019 and 2021 at 15 US hospitals participating in the Cardiogenic Shock Working Group registry. The primary end point was in-hospital mortality. Inverse probability of treatment-weighted logistic regression models were used to estimate odds ratios (ORs) and corresponding 95% confidence intervals (CI), accounting for multiple variables at admission. The association between the timing of PAC placement and in-hospital death was also analyzed. A total of 1055 patients with HF-CS were included, of whom 834 (79%) received a PAC during their hospitalization. In-hospital mortality risk for the cohort was 24.7% (n = 261). PAC use was associated with lower adjusted in-hospital mortality risk (22.2% vs 29.8%, OR 0.68, 95% CI 0.50-0.94). Similar associations were found across SCAI stages of shock, both at admission and at maximum SCAI stage during hospitalization. Early PAC use (≤6 hours of admission) was observed in 220 PAC recipients (26%) and associated with a lower adjusted risk of in-hospital mortality compared with delayed (≥48 hours) or no PAC use (17.3% vs 27.7%, OR 0.54, 95% CI 0.37-0.81).
CONCLUSIONS
This observational study supports PAC use, because it was associated with decreased in-hospital mortality in HF-CS, especially if performed within 6 hours of hospital admission.
CONDENSED ABSTRACT
An observational study from the Cardiogenic Shock Working Group registry of 1055 patients with HF-CS showed that pulmonary artery catheter (PAC) use was associated with a lower adjusted in-hospital mortality risk (22.2% vs 29.8%, odds ratio 0.68, 95% confidence interval 0.50-0.94) compared with outcomes in patients managed without PAC. Early PAC use (≤6 hours of admission) was associated with a lower adjusted risk of in-hospital mortality compared with delayed (≥48 hours) or no PAC use (17.3% vs 27.7%, odds ratio 0.54, 95% confidence interval 0.37-0.81).

Identifiants

pubmed: 37187230
pii: S1071-9164(23)00153-7
doi: 10.1016/j.cardfail.2023.05.001
pii:
doi:

Types de publication

Observational Study Multicenter Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1234-1244

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL159089
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Manreet K Kanwar (MK)

Cardiovascular Institute at Allegheny Health Network, Pittsburgh, Pennsylvania.

Vanessa Blumer (V)

Department of Cardiovascular Medicine, Heart and Vascular Institute, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio.

Yijing Zhang (Y)

The Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts.

Shashank S Sinha (SS)

Inova Heart and Vascular Institute, Inova Fairfax Campus, Falls Church, Virginia.

Arthur R Garan (AR)

Beth Israel Deaconess Medical Center, Boston, Massachusetts'.

Jaime Hernandez-Montfort (J)

Baylor Scott & White Health, Advanced Heart Failure Program Clinic, Temple, Texas.

Adnan Khalif (A)

Cardiovascular Institute at Allegheny Health Network, Pittsburgh, Pennsylvania.

Gavin W Hickey (GW)

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Jacob Abraham (J)

Center for Cardiovascular Analytics, Research and Data Science, Providence Heart Institute, Portland, OR.

Claudius Mahr (C)

University of Washington Medical Center, Seattle, Washington.

Borui Li (B)

The Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts.

Paavni Sangal (P)

The Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts.

Karol D Walec (KD)

The Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts.

Peter Zazzali (P)

The Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts.

Rachna Kataria (R)

Lifespan Cardiovascular Institute, Brown University, Providence, Rhode Island.

Mohit Pahuja (M)

University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.

VAN-Khue Ton (VK)

Massachusetts General Hospital, Boston, Massachusetts.

Neil M Harwani (NM)

The Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts.

Detlef Wencker (D)

Baylor Scott & White Advanced Heart Failure Clinic, Dallas, Texas.

Sandeep Nathan (S)

University of Chicago, Chicago, Illinois.

Esther Vorovich (E)

Northwestern Medicine, Chicago, Illinois.

Shelley Hall (S)

Baylor Scott & White Advanced Heart Failure Clinic, Dallas, Texas.

Wissam Khalife (W)

University of Texas Medical Branch, Galveston, Texas.

Song Li (S)

University of Washington Medical Center, Seattle, Washington.

Andrew Schwartzman (A)

Maine Medical Center, Portland, Maine.

J U Kim (JU)

Houston Methodist Research Institute, Houston, Texas.

Oleg Alec Vishnevsky (OA)

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Ludovic Trinquart (L)

Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston and Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA.

Daniel Burkhoff (D)

Cardiovascular Research Foundation, New York, New York.

Navin K Kapur (NK)

The Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts. Electronic address: Nkapur@tuftsmedicalcenter.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH